Showing results (171-180 of 211) with videos related to

Sort By:
Pageof 22
American Journal of Physiology. Lung Cellular and Molecular Physiology|February 7, 2012
A brief overview of mouse models of pulmonary arterial hypertension: problems and prospectsJose Gomez-Arroyo, Sheinei J Saleem, Shiro Mizuno, et al.
Computers in Biology and Medicine|April 15, 2023
Tumour growth: An approach to calibrate parameters of a multiphase porous media model based on in vitro observations of Neuroblastoma spheroid growth in a hydrogel microenvironmentSilvia Hervas-Raluy, Barbara Wirthl, Pedro E Guerrero, et al.
Frontiers in Cardiovascular Medicine|June 11, 2025
Effectiveness and safety of rivaroxaban in patients with atrial fibrillation and heart failure in clinical practice: an indirect comparison of national and international registriesJose Maria Cepeda, Nicolas Manito, Alejandro Recio Mayoral, et al.
Chest|March 19, 2017
p53 Signaling Pathway Polymorphisms Associated With Emphysematous Changes in Patients With COPDShiro Mizuno, Takeshi Ishizaki, Maiko Kadowaki, et al.
The European Respiratory Journal|April 4, 2020
Angiotensin converting enzyme 2 and angiotensin (1-7) axis in pulmonary arterial hypertensionJulio Sandoval, Leonardo Del Valle-Mondragón, Felipe Masso, et al.
The Prostate|September 16, 2011
Ghrelin receptor as a novel imaging target for prostatic neoplasmsChen Lu, Mark S McFarland, Rae-Lynn Nesbitt, et al.
Clinical Nutrition (Edinburgh, Scotland)|September 28, 2010
Gene variations of nitric oxide synthase regulate the effects of a saturated fat rich meal on endothelial functionJavier Delgado-Lista, Antonio Garcia-Rios, Pablo Perez-Martinez, et al.
EMBO Molecular Medicine|April 8, 2024
FOXF1 promotes tumor vessel normalization and prevents lung cancer progression through FZD4Fenghua Bian, Chinmayee Goda, Guolun Wang, et al.
European Heart Journal|July 15, 2025
Artificial intelligence in cardiovascular pharmacotherapy: applications and perspectivesFrancesco Costa, Juan Jose Gomez Doblas, Arancha Díaz Expósito, et al.
Clinical Lung Cancer|November 24, 2004
Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancerAngel Artal-Cortés, Jose Gomez-Codina, Jose Luis Gonzalez-Larriba, et al.
Pageof 22